Reacción a "A meta-analysis concludes that intravenous ketamine is effective in reducing depressive and suicidal symptoms in patients with major depression"

This is a systematic review and meta-analysis of high methodological quality, published in JAMA Psychiatry, analyzing 26 randomized clinical trials with more than 1,100 patients. Overall, the conclusions are well supported by the data: intravenous ketamine shows a rapid reduction (within hours) in depressive and suicidal symptoms, with moderate to large effect sizes, especially within the first 24 hours. This is clinically very relevant, as no currently available treatment acts this quickly in situations of acute suicidal risk.

The study fits well with the evidence accumulated in recent years and reinforces it. It confirms that ketamine can produce rapid improvements in depressive distress that conventional antidepressants cannot achieve in such a short time frame. In fact, this body of evidence is already beginning to have regulatory impact: recently, France has approved its use in certain clinical contexts for severe suicidal symptoms.

Even so, there are important limitations to consider. There is some heterogeneity among the included studies, and in some cases the dissociative effects of ketamine may have compromised blinding, as patients may guess which treatment they received. In addition, most trials have small sample sizes and, importantly, there is very limited data on long-term safety and efficacy, since studies focus on the acute effect.

As for its implications, these results are particularly relevant for patients with treatment-resistant depression and for suicidal crises requiring urgent intervention. However, it is not a general treatment for depression, and its use raises key questions about how, where, and under what supervision it should be administered. It is also important to consider the potential for abuse and possible long-term adverse effects before expanding its use.

Overall, this meta-analysis reinforces the idea that we are dealing with a potentially very valuable therapeutic tool in specific clinical contexts, especially because of its rapid onset of action. However, it also highlights that we are still at a relatively early stage, and that the real challenge is not only to demonstrate short-term efficacy, but to define how to integrate it safely, sustainably, and in an evidence-based manner into healthcare systems.